Immunic (IMUX) Competitors $0.96 0.00 (-0.06%) Closing price 02/10/2025 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.41%) As of 05:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMUX vs. ALLO, PRME, OLMA, MBX, CRVS, TRVI, KRRO, TNGX, KOD, and TSHAShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Allogene Therapeutics (ALLO), Prime Medicine (PRME), Olema Pharmaceuticals (OLMA), MBX Biosciences (MBX), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), Korro Bio (KRRO), Tango Therapeutics (TNGX), Kodiak Sciences (KOD), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Allogene Therapeutics Prime Medicine Olema Pharmaceuticals MBX Biosciences Corvus Pharmaceuticals Trevi Therapeutics Korro Bio Tango Therapeutics Kodiak Sciences Taysha Gene Therapies Allogene Therapeutics (NASDAQ:ALLO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk. Which has better earnings and valuation, ALLO or IMUX? Immunic has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$90K3,447.91-$327.27M-$1.56-0.95ImmunicN/AN/A-$93.61M-$1.23-0.78 Do institutionals & insiders hold more shares of ALLO or IMUX? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by company insiders. Comparatively, 3.0% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor ALLO or IMUX? In the previous week, Allogene Therapeutics had 4 more articles in the media than Immunic. MarketBeat recorded 9 mentions for Allogene Therapeutics and 5 mentions for Immunic. Allogene Therapeutics' average media sentiment score of 0.55 beat Immunic's score of 0.12 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ALLO or IMUX? Allogene Therapeutics received 179 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 65.57% of users gave Allogene Therapeutics an outperform vote while only 64.33% of users gave Immunic an outperform vote. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes28065.57% Underperform Votes14734.43% ImmunicOutperform Votes10164.33% Underperform Votes5635.67% Do analysts recommend ALLO or IMUX? Allogene Therapeutics presently has a consensus target price of $9.73, suggesting a potential upside of 557.66%. Immunic has a consensus target price of $12.67, suggesting a potential upside of 1,219.31%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Allogene Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is ALLO or IMUX more profitable? Allogene Therapeutics' return on equity of -52.13% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.13% -41.29% Immunic N/A -169.55%-118.96% Which has more volatility and risk, ALLO or IMUX? Allogene Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. SummaryAllogene Therapeutics beats Immunic on 10 of the 16 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.29M$7.01B$5.75B$9.06BDividend YieldN/A2.91%5.30%4.01%P/E RatioN/A5.0064.2115.78Price / SalesN/A325.69998.3875.82Price / CashN/A75.4646.0638.79Price / Book1.505.635.134.78Net Income-$93.61M$123.93M$113.50M$222.19M7 Day Performance1.06%-1.19%-0.51%0.25%1 Month Performance-8.56%-0.40%3.88%3.05%1 Year Performance-21.30%5.40%22.48%20.50% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic3.668 of 5 stars$0.96-0.1%$12.67+1,219.3%-21.3%$88.29MN/A0.0070Analyst DowngradeNews CoverageGap UpALLOAllogene Therapeutics2.8341 of 5 stars$1.66-8.1%$9.73+488.1%-66.2%$347.00M$90,000.00-1.06310PRMEPrime Medicine3.5262 of 5 stars$2.65-5.5%$13.13+396.2%-64.1%$346.26MN/A-1.29234Analyst UpgradeNews CoverageOLMAOlema Pharmaceuticals1.5726 of 5 stars$6.00-1.8%$28.75+379.2%-66.9%$342.43MN/A-2.7370MBXMBX Biosciences2.6082 of 5 stars$9.96-0.5%$37.25+274.2%N/A$333.53MN/A0.0036News CoverageGap UpCRVSCorvus Pharmaceuticals1.8265 of 5 stars$5.09-5.0%$12.38+143.1%+127.1%$327.08MN/A-5.4730Gap DownTRVITrevi Therapeutics1.9939 of 5 stars$4.17+5.9%$9.31+123.1%+147.6%$320.86MN/A-9.4920KRROKorro Bio1.2011 of 5 stars$34.03-0.3%$144.00+323.2%-43.4%$318.86MN/A0.0070Positive NewsGap DownTNGXTango Therapeutics3.3119 of 5 stars$2.92-2.2%$13.14+350.9%-78.0%$313.13M$36.53M-2.4790Analyst RevisionKODKodiak Sciences4.2028 of 5 stars$5.88-8.1%$8.00+36.1%-0.7%$309.35MN/A-1.6190TSHATaysha Gene Therapies2.6761 of 5 stars$1.49-1.0%$6.63+346.1%+11.3%$304.34M$15.45M2.36180 Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Prime Medicine Alternatives Olema Pharmaceuticals Alternatives MBX Biosciences Alternatives Corvus Pharmaceuticals Alternatives Trevi Therapeutics Alternatives Korro Bio Alternatives Tango Therapeutics Alternatives Kodiak Sciences Alternatives Taysha Gene Therapies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMUX) was last updated on 2/11/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredTrump’s “Shock and Awe” Executive OrderPresident Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn fro...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
